Recent developments in the treatment of rheumatoid arthritis with targeted biological agents

Bibliography

• ARNETT FC, EDWORTHY SM, BLOCH DA, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. (1988) 31:315–324.
   PubMed Web of Science ®Google Scholar
• AKIRA S, HIRANO T, TAGA T, KISHIMOTO I: Biology of multi-functional cytokines: IL-6 acid related molecules (IL-1 and TNF). FASEB J. (1990) 4:2860–2867.
   PubMed Web of Science ®Google Scholar
• KIM KU, KWON 0J, JUE DM: Pro-tumour necrosis factor cleavage factor enzyme in macro-phages membrane particulate. Immunology (1993) 83:134–139.
   Google Scholar
• HERZYK DJ, BERGER AE, ALLEN JN, WERNER MD: Sandwich ELISA formats designed to detect 17 lcDa IL-113 significantly underestimates 35 kDa IL-1I3. I Immunol. Method (1992) 148:243–254.
   PubMed Web of Science ®Google Scholar
• WILSON KP, BLACK J-AF, THOMSON JA, et al.: Structure and mechanism of action of inter-leukin-113 converting enzyme. Nature (1994) 370:270–275.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, GREENE it, TAN P, et al.: Co-expression and functional co-operation of CTLA4 and CD28 on activated lymphocytes. I Exp. Med. (1992) 176:1595–1604.
   PubMed Web of Science ®Google Scholar
• COLOTTA F, RE F, MUZIO M: Interleukin-1 type receptor: a decoy target for IL-1 that is regulated by IL-4. Science (1993) 261:472–475.
   PubMed Web of Science ®Google Scholar
• SECKINGER P, VEY E, TURCATTI G, WINGFIELD P, DAYER JM: TNF inhibitor: purification, NH2 terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities. Eur. I Immunol. (1990) 20:1167–1174.
   PubMed Web of Science ®Google Scholar
• MACKAY CR, IMHOF BA: Cell adhesion in the immune system. Immunol. Today (1993) 14:99–102.
   PubMedGoogle Scholar
• HANAMALTER R, KOOLWIJK P, LE CLERCQ L: Regulation of metalloproteinase expression in human vein and microvascular endothelial cells. Biochem. 1 (1993) 296:803–809.
   PubMed Web of Science ®Google Scholar
• STEVENS CR, BLAKE DR, MERRY P, et al.: A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum. (1991) 34:1508–1513.
   PubMed Web of Science ®Google Scholar
• ANGGARD E: Nitric oxide: mediator, murderer and medicine. Lancet (1994) 343:1199–1206.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC, GROSSMAN AS: Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop. Bailliere's Clinical Rheumatology (1996) 10:199–225.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN G, BOYLE DL, YU C, et al.: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. (1994) 37:644–652.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC, ROUX-LOMBARD P, DAYER J-M, PANAYI GS: Dysregulated interleukin-1 receptor antagonist protein production in rheumatoid arthritis; pathogenetic implications. Ar-thritis Rheum. (1995) 38:642–648.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC: The neuroendocrine immunology of rheumatoid arthritis. Bailliere 's Clinical Rheumatology (1996) 10:273–293.
   PubMed Web of Science ®Google Scholar
• AREND WP, DAYER JM: Inhibition of the production and effects of interleukin-1 and tumour necrosis alpha in rheumatoid arthritis. Arthritis Rheum. (1995) 38:151–160.
   PubMed Web of Science ®Google Scholar
• PINCUS T: The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin. Arthritis Rheum. (1992) 21:2–15.
   PubMed Web of Science ®Google Scholar
• BOERS M, TUGWELL P, FELSTON DT, et al.: WHO and ILAR core end points for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. I Rheumatol. (1994) 21:86–89.
   Web of Science ®Google Scholar
• WOLFE F, HAWLEY DJ, CATHEY MA: Clinical and health status measures over time - prognosis and outcome assessment in RA. I Rheumatol. (1991) 18:1290–1297.
   Web of Science ®Google Scholar
• GABRIEL SE, LUTHRA HS: Rheumatoid arthritis: can long-term outcome be altered Mayo Clin. Proc. (1988) 63:58–68.
   PubMed Web of Science ®Google Scholar
• FELSTON D, ANDERSON J, MEENAN R: The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. (1994) 37:1487–1499.
   PubMed Web of Science ®Google Scholar
• BRENNAN FM, CHANTRY D, JACKSON A, et al.: Inhibitory effects of TNF-a antibodies on synovial cell IL-113 production in RA. Lancet (YEAR) ii:244–247.
   PubMedGoogle Scholar
• ELLIOT MJ, MAINI RN, FELDMAN M, et al.: Treatment of rheumatoid arthritis with chimaeric mAb to TNF-a. Arthritis Rheum. (1993) 36:1681–1690.
   PubMed Web of Science ®Google Scholar
• ELLIOT MJ, MAINI RN, FELDMAN M, et al. : Randomised double-blind comparison of chimaeric antibody to TNF-a (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• ELLIOT M, MAINI R, FELDMAN M, et al.: Repeated therapy with mAb to TNF-oc (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344:1125–1127.
   PubMed Web of Science ®Google Scholar
• PALEOLOG EM, TAYLOR PC, HUNT M, et al.: Treatment of rheumatoid arthritis with antibody to TNF-a decreases expression of and shedding of E-selectin. Arthritis Rheum. (1995) 38:S279.
   Web of Science ®Google Scholar
• RANKIN ECC, CHOY EHS, EHRENSTEIN MR, et al.: A double-blind, placebo ascending dose trial of the recombinant humanised anti-TNF-a antibody CDP571 in patients with RA. ArthritisRheum. (1994) 37:S295.
   Google Scholar
• RANKIN ECC, CHOY EHS, EHRENSTEIN MR, et al.: Serological effects of repeated doses of an engineered anti-TNF-a mAb, CDP571 in patients with RA. Arthritis Rheum. (1995) 38:S279.
   Web of Science ®Google Scholar
• MALAISE MG, RIBBENS C, KAYE 0 et al.: A synovial soluble TNF-receptor (60 and 80 kDa) level imbalance reflects erosive disease in RA. Arthritis Rheum. (1994) 37:S193.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, MARGOLIES GR, HECK LW, et al.: Soluble tumour necrosis factor receptor (sTNER): results of a Phase I dose-escalation study in patients with RA. Arthritis Rheum. (1994) 37:S295.
   Google Scholar
• SANDER O, RAU R, RIEL P, et al.: Neutralisation of TNF-a by lenercept (TNE5R55-IgGl, Ro 45-2081) in patients with RA treated for 3 months. Arthritis Rheum. (1996) 39:S242.
   Web of Science ®Google Scholar
• HASLER F, VAN DE PUTTE L, BAUDIN M et al.: Chronic TNF-a neutralisation up to 1 year by lenercept in patients with RA: results of an open label extension of a double-blind single dose Phase 1 study. Arthritis Rheum. (1996) 39:S243.
   Web of Science ®Google Scholar
• GEARING AJH, BECKETT P, CHRISTODOULOU M, et al.: Processing of tumor necrosis factor alpha precursors by metalloproteinase. Nature (1994) 370:555–557.
   PubMed Web of Science ®Google Scholar
• THIEL M, BARDENHEUER H, POCH G, MADEL C, PETER K: Pentoxyfylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymor-phonuclear leukocytes. Biochem. Biophys. Res. Commun. (1991) 180:53–58.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, AVINA-ZUBIETA A, LUONG MH, RUSSEL AS: An open study of pentoxyfylline in the treatment of severe refractory RA. J. Rheumatol. (1995) 22:625–629.
   PubMed Web of Science ®Google Scholar
• BEAVO JA, REISFELD DH: Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol. Sci. (1990) 11:150–161.
   PubMed Web of Science ®Google Scholar
• SEMMLER JII, WACHTEL H, ENDRES S: The specific type IV phosphodiesterase inhibitor rolipram suppresses TNF-a production by human mononuclear cells. Int. J. Immunopharmacol. (1993) 15:409–418.
   PubMed Web of Science ®Google Scholar
• SUTTORP N, WEBER U, WELSCH T, SCHUDT C: Role of phosphodiesterase in the regulation of endothelial permeability in vitro. J. Clin. Invest. (1993) 91:1421–1426.
   PubMed Web of Science ®Google Scholar
• SOMMER N, LOSCHMANN PA, NORTHOFF GH, et al.: The anti-depressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Medicine (1995) 1:244–248.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC, JAWED S, BLAKE DR, et al.: Treatment of patients with RA with RP73401 phosphodiesterase type 4 inhibitor. Arthritis Rheum. (1996) 39:S282.
   Web of Science ®Google Scholar
• DREVLOW BE, LOVIS R, HAAG MA, et al.: Recombinant human interleukin-1 receptor type 1 in the treatment of patients with active RA. Arthritis Rheum. (1996) 39:257–265.
   PubMed Web of Science ®Google Scholar
• BESEDOVSKY H, DEL ROY A, SORKIN E, DINARELLO C: Immunoregulatory feedback between IL-1 and the glucocorticoid hormones. Science (1986) 233:652–666.
   PubMed Web of Science ®Google Scholar
• AREND WP, MALYAK M, SMITH MF, et al.: Binding of IL-la, IL-113 and IL-1Ra by soluble IL-1 receptors and levels of soluble IL-1 receptors by synovial fluid. J. Immunol. (1994) 153:4766–4774.
   PubMed Web of Science ®Google Scholar
• SVENSON M, HANSEN MB, HEEGARD P, ABELL K, BENDTZEN K: Specific binding of IL-113 and IL-1Ra to human serum: high affinity binding of IL-1Ra to soluble IL-1 receptor type 1. Cytokine (1993) 5:427–435.
   PubMed Web of Science ®Google Scholar
• POPE RM, DREVLOW BE, CAPEZIO J, et al.: Intra-articular administration of recombinant human IL-1 receptor type 1 in patients with active RA. In: Biologic Agents in Autoimmune Disease IV. In press.
   Google Scholar
• SADOUK M, PELLETIER JP, TARDIF K, et al.: Co-expression of IL-1R1 and IL-1R2 in human OA synovial fibroblasts: binding and biological activity is mediated exclusively by type! receptor. Arthritis Rheum. (1994) 37:S306.
   Google Scholar
• AREND WP, DAYER JM: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. (1990) 33:305–315.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN GS, BOYLE D, YU C, et al.: Synovial interleukin-1 receptor antagonist and interleukin 1 balance in rheumatoid arthritis. Arthritis Rheum. (1994) 37:644–652.
   PubMed Web of Science ®Google Scholar
• LEDSACK ME, PAUL ME, BLOEDOW DC, et al.: Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. (1991) 34:S45.
   Google Scholar
• LEDSACK ME, PAUL CC, MARTINDALE JJ, CATALANO MA: A dose and regimen ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. (1993) 36:S39.
   PubMedGoogle Scholar
• ROESSLER FJ, ALLEN ED, WILSON JM, HARTMAN JVV, DAVIDSON BL: Adenoviral-mediated gene transfer to rabbit synovium in vivo. J. Clin. Invest. (1993) 92:1085–1092.
   PubMed Web of Science ®Google Scholar
• HARTMAN JVV, DAVIDSON BL, ROESSLER FJ: Genetic modification of synoviocytes in vivo using recombinant adenoviral vectors [abstract]. Arthritis Rheum. (1993) 36:S64.
   Google Scholar
• BANDARA G, MUELLER GM, GALEA-LAURI J, et al.: Intra-articular expression of biologically active interleukin-1 receptor antagonist protein by ex-vivo gene transfer. Proc. Natl. Acad. Sci. USA (1993) 90:10764–10768.
   PubMed Web of Science ®Google Scholar
• HARDING MW, KU G, FAUST T, LAUFFER LL, LIVINGSTONE D: Interleukin-113 converting enzyme inhibition blocks progression of type 2 collagen-induced arthritis in mice. Arthritis Rheum. (1995) 38:S400.
   Web of Science ®Google Scholar
• WILLIAMS RO, MASON LM, FELDMANN, MAINI R: Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen induced arthritis. Proc. Natl. Acad. Sci. USA (1994) 91:2762–2766.
   PubMed Web of Science ®Google Scholar
• JOOSTEN LAB, HELSEN MMA, VAN DE LOO FAJ, VAN DE BERG WB: Anticytokine treatment of established type 2 collagen-induced arthritis in DBA/1 mice): a comparative study using anti-TNF-a, anti-IL-113/a and IL-1Ra. Arthritis Rheum. (1996) 39:797–809.
   PubMed Web of Science ®Google Scholar